PAR paradigm biopharmaceuticals limited..

We just submitted an IND - So now what?, page-5

  1. 1,625 Posts.
    lightbulb Created with Sketch. 677

    Cheers Mozz

    This is kind of in response to a discussion on another thread (on temazumab) but is really about the different trials so thought I would post here.

    Took some time to unpick the trial design for these one registered so far.
    002 - https://clinicaltrials.gov/ct2/show/record/NCT04809376
    006 - https://clinicaltrials.gov/ct2/show/record/NCT04814719
    008 - http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381039

    Summarised here with a bit of license used to abbreviate some of the endpoints. Might help to understand some of the thinking in how they all interact (so when you work it out please let me know . But just a couple of observations...
    - 008 also contains many of the key endpoints in the pivotal 002 (hence the 'lookthrough' for potential partnering discussions).
    - 006 doesnt seem to have biomarker data?
    - 008 also looking at biomarkers in serum and urine. I wonder if they are trying to correlate that to synovial fluid data, then possibly adding it to 006 (if it correlates well much easier to measure that than synovial fluid).
    - 002 has changes in ECG which is a new one
    https://hotcopper.com.au/data/attachments/3041/3041078-f87c36e3322887083111672f7765c16d.jpg
    Last edited by Torpy: 27/03/21
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
46.5¢
Change
0.010(2.20%)
Mkt cap ! $184.8M
Open High Low Value Volume
45.5¢ 48.0¢ 44.0¢ $534.2K 1.168M

Buyers (Bids)

No. Vol. Price($)
1 5245 45.5¢
 

Sellers (Offers)

Price($) Vol. No.
47.0¢ 10000 1
View Market Depth
Last trade - 16.10pm 04/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.